STUDY OBJECTIVE: To describe the impact of highly active antiretroviral therapy (HAART) on mortality, morbidity, and markers of HIV disease progression in HIV infected women. DESIGN: Data collected from the Women's Interagency HIV Study, a prospective cohort study that enrolled women between October 1994 and November 1995. SETTING: Six clinical consortia based in five cities in the United States (New York, NY; Washington, DC; Los Angeles, CA; San Francisco, CA; and Chicago, IL). PARTICIPANTS: A total of 1691 HIV seropositive women with a study visit after April 1996. MAIN RESULTS: Beginning in April 1996, the self reported use of HAART increased over time, with more than 50% of the cohort reporting HAART use in 1999. There was a 23% decline per semester in the incidence of AIDS from April 1996 (95% confidence intervals (CI) -29% to -16%). Furthermore, there was a 21% decline of the semiannual mortality rates among those with AIDS at baseline (95% CI -27% to -14%) and an 11% decline among those AIDS free at baseline (95% CI -3% to -18%). CD4+ lymphocyte counts either increased (women with baseline AIDS) or stabilised (women without baseline AIDS) after April 1996, and HIV RNA levels dramatically declined in both groups, although the percentage of women with HIV RNA above 4000 cps/ml remained stable at approximately 40% since mid-1997. CONCLUSIONS: Despite concerns regarding the use of antiretroviral therapies in this population, the use of therapies led to improved immunological function, suppressed HIV disease activity, and dramatic declines in morbidity and mortality.
STUDY OBJECTIVE: To describe the impact of highly active antiretroviral therapy (HAART) on mortality, morbidity, and markers of HIV disease progression in HIV infectedwomen. DESIGN: Data collected from the Women's Interagency HIV Study, a prospective cohort study that enrolled women between October 1994 and November 1995. SETTING: Six clinical consortia based in five cities in the United States (New York, NY; Washington, DC; Los Angeles, CA; San Francisco, CA; and Chicago, IL). PARTICIPANTS: A total of 1691 HIV seropositive women with a study visit after April 1996. MAIN RESULTS: Beginning in April 1996, the self reported use of HAART increased over time, with more than 50% of the cohort reporting HAART use in 1999. There was a 23% decline per semester in the incidence of AIDS from April 1996 (95% confidence intervals (CI) -29% to -16%). Furthermore, there was a 21% decline of the semiannual mortality rates among those with AIDS at baseline (95% CI -27% to -14%) and an 11% decline among those AIDS free at baseline (95% CI -3% to -18%). CD4+ lymphocyte counts either increased (women with baseline AIDS) or stabilised (women without baseline AIDS) after April 1996, and HIV RNA levels dramatically declined in both groups, although the percentage of women with HIV RNA above 4000 cps/ml remained stable at approximately 40% since mid-1997. CONCLUSIONS: Despite concerns regarding the use of antiretroviral therapies in this population, the use of therapies led to improved immunological function, suppressed HIV disease activity, and dramatic declines in morbidity and mortality.
Authors: R Andersen; S Bozzette; M Shapiro; P St Clair; S Morton; S Crystal; D Goldman; N Wenger; A Gifford; A Leibowitz; S Asch; S Berry; T Nakazono; K Heslin; W Cunningham Journal: Health Serv Res Date: 2000-06 Impact factor: 3.402
Authors: N A Hessol; K Anastos; A M Levine; N Ameli; M Cohen; M Young; M Augenbraun; P Miotti; S J Gange Journal: AIDS Res Hum Retroviruses Date: 2000-08-10 Impact factor: 2.205
Authors: K Anastos; S J Gange; B Lau; B Weiser; R Detels; J V Giorgi; J B Margolick; M Cohen; J Phair; S Melnick; C R Rinaldo; A Kovacs; A Levine; S Landesman; M Young; A Muñoz; R M Greenblatt Journal: J Acquir Immune Defic Syndr Date: 2000-07-01 Impact factor: 3.731
Authors: Valerie Wojna; Richard L Skolasky; Rosa Hechavarría; Rául Mayo; Ola Selnes; Justin C McArthur; Loyda M Meléndez; Elizabeth Maldonado; Carmen D Zorrilla; Hermes García; Edmundo Kraiselburd; Avindra Nath Journal: J Neurovirol Date: 2006-10 Impact factor: 2.643
Authors: L Stewart Massad; Xianhong Xie; Robert Burk; Marla J Keller; Howard Minkoff; Gypsyamber DʼSouza; D Heather Watts; Joel Palefsky; Mary Young; Alexandra M Levine; Mardge Cohen; Howard D Strickler Journal: AIDS Date: 2014-11-13 Impact factor: 4.177
Authors: Manuela García de la Hera; Inmaculada Ferreros; Julia del Amo; Patricia García de Olalla; Santiago Pérez Hoyos; Roberto Muga; Jorge del Romero; Rafael Guerrero; Ildefonso Hernández-Aguado Journal: J Epidemiol Community Health Date: 2004-11 Impact factor: 3.710
Authors: Regis Kreitchmann; Karen Megazzini; Victor Hugo Melo; Débora Fernandes Coelho; D Heather Watts; Margot Krauss; Maria Isabel Gouvea; Geraldo Duarte; Marcelo H Losso; George K Siberry Journal: AIDS Care Date: 2015-08-19
Authors: Meredith S Shiels; Stephen R Cole; Joan S Chmiel; Joseph Margolick; Jeremy Martinson; Zuo-Feng Zhang; Lisa P Jacobson Journal: J Clin Epidemiol Date: 2009-10-31 Impact factor: 6.437